New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 21, 2012
09:03 EDTOREXBlue Chip says Orexigen accelerating patient enrollment for The Light Study
Blue Chip Patient Recruitment, a division of Blue Chip Marketing Worldwide, said it has partnered with Orexigen Therapeutics to accelerate patient enrollment of The Light Study, Orexigenís cardiovascular outcomes trial evaluating Contrave, an investigational medication being evaluated for the treatment of obesity. Approximately 9,000 patients will be randomized in the study within the next few weeks, nearly 14 months ahead of original forecasts, Blue Chip said.
News For OREX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 6, 2015
06:51 EDTOREXOrexigen price target lowered to $11 from $21 at Piper Jaffray
Piper Jaffray analyst Charles Duncan cut his price target for Orexigen shares to $11 saying traction for Contrave, while good, is slightly below his expectations. He continues to view Contrave as a "novel asset" with large market potential of $700M in annual revenue, however. Duncan views the company's current market capitalization of $270M as a "market inefficiency" relative to the potential of the Contrave franchise. Duncan reiterates an Overweight rating on Orexigen.
October 1, 2015
08:46 EDTOREXOrexigen announces submission of Contrave NDA in South Korea
Subscribe for More Information
September 23, 2015
08:39 EDTOREXOrexigen receives payments for $22M from U.S. and Korean partners
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use